Annual report pursuant to Section 13 and 15(d)

Licenses Acquired (Tables)

v3.22.1
Licenses Acquired (Tables)
12 Months Ended
Dec. 31, 2021
Licenses Acquired  
Schedule of Research and Development-Licenses

For the years ended December 31, 2021 and 2020, the Company’s research and development-licenses acquired are comprised of the following:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

($ in thousands)

    

2021

    

2020

Partner companies:

 

​

  

 

​

  

JMC

​

$

13,819

​

$

—

Mustang

​

​

1,630

​

​

2,489

Other

​

​

176

​

​

345

Total

​

$

15,625

​

$

2,834

Schedule of Research and Development for Licenses Acquired

For the years ended December 31, 2021 and 2020 Mustang recorded the following expense in research and development – licenses acquired:

​

​

​

​

​

​

​

​

​

​

For the Year Ended December 31, 

($ in thousands)

    

2021

    

2020

City of Hope National Medical Center

​

​

​

​

​

​

CD123 (MB-102)

​

$

250

​

$

334

IL13Rα2 (MB-101)

​

​

—

​

​

334

HER2 (MB-103)

​

​

—

​

​

500

CS1 (MB-104)

​

​

—

​

​

200

PSCA (MB-105)

​

 

250

​

 

200

Spacer

​

​

—

​

​

334

Mayo Clinic

​

​

750

​

​

—

Fred Hutchinson Cancer Research Center - CD20 (MB-106)

​

​

—

​

​

300

Leiden University Medical Centre (MB-110)

​

​

350

​

​

—

CSL Behring (Calimmune) (MB-107)

​

​

30

​

​

170

SIRION Biotech LentiBOOSTTM (MB-207)

​

​

—

​

​

117

Total

​

$

1,630

​

$

2,489